Targeting platelets for the treatment of cancer
|dc.identifier.citation||Elaskalani, O. and Berndt, M. and Falasca, M. and Metharom, P. 2017. Targeting platelets for the treatment of cancer. Cancers. 9 (7): 94.|
The majority of cancer-associated mortality results from the ability of tumour cells to metastasise leading to multifunctional organ failure and death. Disseminated tumour cells in the blood circulation are faced with major challenges such as rheological shear stresses and cell-mediated cytotoxicity mediated by natural killer cells. Nevertheless, circulating tumour cells with metastatic ability appear equipped to exploit host cells to aid their survival. Despite the long interest in targeting tumour-associated host cells such as platelets for cancer treatment, the clinical benefit of this strategy is still under question. In this review, we provide a summary of the latest mechanistic and clinical evidence to evaluate the validity of targeting platelets in cancer.
|dc.title||Targeting platelets for the treatment of cancer|
|curtin.faculty||Faculty of Health Sciences|